SEC Form 4
Ardelyx, Inc. (ARDX) insider trading
In the 12 months to Nov 21, 2026, 2 ARDX insiders reported open-market sales of $2.3M across 8 filings; one director bought $1.9M.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $2.3M
- 8 filings · 2 insiders
- Open-market purchases
- $1.9M
- 1 filing · David M. Mott, Director
- Pre-arranged sales (10b5-1)
- 8 of 8
- All $2.3M sold was pre-arranged
Who traded ARDX, and when
- Purchase
- Sale
- Sale, pre-arranged (10b5-1)
ARDX daily close from Nov 21, 2025 to Nov 20, 2026, between $2.88 and $7.99, last $2.99. 8 sale and 1 purchase filings by 3 insiders, marked at their filing dates. David M. Mott, Director: bought $1.9M across 1 filing, first filed Feb 23, 2026, last Feb 23, 2026. Michael Raab, President & CEO: sold $1.5M across 6 filings, first filed Feb 25, 2026, last Jul 17, 2026. Laura A. Williams, Chief Patient Officer: sold $839.4K across 2 filings, first filed Jan 9, 2026, last Jun 22, 2026.
Largest mark · tap a row for others
David M. Mott · Director
Purchase $1,946,331
333,333 shares at $5.84 avg
Filed Feb 23, 2026 · traded Feb 20
Close on filing date $5.75
David M. Mott · Director
Director
$1.9M boughtMichael Raab · President & CEO
President & CEO
$1.5M soldLaura A. Williams · Chief Patient Officer
Chief Patient Officer
$839.4K soldOpen-market trades
9 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| David M. Mott | Director | — | $1.9M | 1 | — | |
| Michael Raab | President & CEO | $1.5M | — | 6 | 100% of sales | |
| Laura A. Williams | Chief Patient Officer | $839.4K | — | 2 | 100% of sales |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | Michael Raab President & CEO | SalePre-arranged (10b5-1) | 41,668 | $5.06 | $210.9K | 1,678,366 | |
traded | Laura A. Williams Chief Patient Officer | SalePre-arranged (10b5-1) | 81,898 | $5.99 | $490.5K | 378,195 | |
traded | Michael Raab President & CEO | SalePre-arranged (10b5-1) | 41,666 | $5.67 | $236.3K | 1,699,200 | |
traded | Michael Raab President & CEO | SalePre-arranged (10b5-1) | 41,666 | $6.28 | $261.6K | 1,774,781 | |
traded | Michael Raab President & CEO | SalePre-arranged (10b5-1) | 41,668 | $6.29 | $262.0K | 1,795,614 | |
traded | Michael Raab President & CEO | SalePre-arranged (10b5-1) | 41,666 | $5.84 | $243.3K | 1,816,448 | |
traded | Michael Raab President & CEO | SalePre-arranged (10b5-1) | 41,666 | $6.26 | $260.6K | 1,836,153 | |
traded | David M. Mott Director | Purchase | 333,333 | $5.84 | $1.9M | 3,302,918 | |
traded | Laura A. Williams Chief Patient Officer | SalePre-arranged (10b5-1) | 50,000 | $6.98 | $348.9K | 361,563 |
GET /stocks/filings/vX/form-4?tickers=ARDX&filing_date.gte=2025-11-21&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"ARDX"
],
"issuer_cik": "0001437402",
"owner_cik": "0001321402",
"accession_number": "0001321402-26-000016",
"form_type": "4",
"filing_date": "2026-07-17",
"period_of_report": "2026-07-15",
"issuer_name": "ARDELYX, INC.",
"issuer_trading_symbol": "ARDX",
"owner_name": "RAAB MICHAEL",
"is_director": true,
"is_officer": true,
"is_ten_percent_owner": false,
"is_other": false,
"officer_title": "President & CEO",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-07-15",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 41668,
"transaction_price_per_share": 5.062,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 1678366,
"transaction_value": 210923.416,
"not_subject_to_section_16": false,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 7, 2025."
},
{
"id": "F2",
"description": "Transaction was executed in multiple trades in prices ranging from $5.03 to $5.12, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."
}
]
},
{
"tickers": [
"ARDX"
],
"issuer_cik": "0001437402",
"owner_cik": "0001869194",
"accession_number": "0001869194-26-000008",
"form_type": "4",
"filing_date": "2026-06-22",
"period_of_report": "2026-06-18",
"issuer_name": "ARDELYX, INC.",
"issuer_trading_symbol": "ARDX",
"owner_name": "Williams Laura A",
"is_director": false,
"is_officer": true,
"is_ten_percent_owner": false,
"is_other": false,
"officer_title": "Chief Patient Officer",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-06-18",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 81898,
"transaction_price_per_share": 5.989,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 378195,
"transaction_value": 490487.122,
"not_subject_to_section_16": false,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."
},
{
"id": "F2",
"description": "Transaction was executed in multiple trades in prices ranging from $5.97 to $6.0086, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."
}
],
"remarks": "Exhibit 24.1 - Power of Attorney"
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 101 records
- Option exercises8 records
- Tax withholding6 records
- Tax withholding (sold to cover)70 records
- Grants and awards17 records
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Pre-arranged (10b5-1)
- The insider marked the filing as made under a trading plan set up in advance (SEC Rule 10b5-1). The mark covers the whole filing, and an unmarked filing may still be under a plan.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.
Frequently asked questions
Has Ardelyx, Inc.'s CEO sold stock?
Yes. Michael Raab (CEO) sold 250,000 shares ($1.5M) between Feb 2026 and Jul 2026, all under a pre-arranged 10b5-1 plan.
How current is ARDX’s insider data?
These are ARDX Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.
What counts as an open-market buy or sell?
Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.
Build with AI
Track ARDX insider trades with your agent
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for ARDX every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.